| Document |
Document Title |
|
WO/2023/017094A1 |
The present invention relates 2,2-difluoro-5H-[l,3]dioxolo[4,5-f]isoindol-7-one derivatives of the formula (I) wherein Q is Qa, Qb or Qc. An exemplary compound is e.g. 6-[3-ethylsulfonyl-6-(trifluoromethyl) imidazo[l,2-a]pyridin-2-yl]-2,...
|
|
WO/2023/016567A1 |
Disclosed is a method for preventing and/or treating a disease or disorder associated with a defect in hemoglobin protein activity or expression or innate immune response, type 1 or type 3 immunity related immune disorder, which comprise...
|
|
WO/2022/200523A9 |
The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compound...
|
|
WO/2023/015559A1 |
The present disclosure discloses a compound, or a pharmaceutically acceptable salt thereof having the structure of Formula (I), and pharmaceutical compositions including the same, that are inhibitors of one or more RAS proteins and are u...
|
|
WO/2023/011446A1 |
Provided are a compound of formula (I), a pharmaceutically acceptable salt thereof, and a preparation method therefor and a use thereof. The compound can be used a drug in the treatment of diseases and disorders comprising cancer, and ot...
|
|
WO/2023/005117A1 |
The present invention provides a preparation method for pranoprofen impurity, comprising the following steps: A) reacting alkali metal and diol to obtain a reaction liquid; B) adding compound 1 to the reaction liquid of step A) to react ...
|
|
WO/2023/009503A1 |
Provided herein are photoactive fluorescent 2-diazo-3-oxo-2,3-dihydrospiro[indene-l,9'-xanthene] derivatives and other similar compounds of formula (I) for use in labeling proteins, for example, tagged proteins, and for use in visualizin...
|
|
WO/2023/007147A1 |
This invention relates to therapeutic 6-substituted naphthalene-1,3- disulfonic acid derivatives of formula (I) (Formula (I)). More specifically, the invention relates to compounds of formula (I) useful as modulators of extracellular nic...
|
|
WO/2023/002323A1 |
The present disclosure includes synthetic methods for preparing certain substituted tricyclic amides, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a subject.
|
|
WO/2023/003656A2 |
Generally discussed herein are techniques for and systems and apparatuses configured to reduce susceptibility to charge noise. A device can include electrical contacts, an atom-like system situated to interact with a first electrical fie...
|
|
WO/2023/003002A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of the pres...
|
|
WO/2023/003973A1 |
Disclosed herein are inhibitors of deubiquitinating (DUB) enzyme USP7 (Ubiquitin Specific Protease 7). Also provided are methods of treating a disease or disorder modulated by USP7.
|
|
WO/2023/004266A1 |
Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the ...
|
|
WO/2023/001028A1 |
A heteroaryl-3-piperidinedione compound and the use thereof. Particularly disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/000398A1 |
Provided in the present invention are a lycorine β-aryl acrylate derivative, and a preparation method therefor and the use thereof. The lycorine β-aryl acrylate derivative has a structure as shown in formula I, wherein Ar is a C6-12 ar...
|
|
WO/2023/002431A1 |
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein L1, L2, L3, R1 R2, M, p, q, m, and n are as defined herein. Additional ...
|
|
WO/2023/284654A1 |
Provided are an organic heterocyclic compound and an application thereof in an organic light emitting diode. The organic compound has improved carrier balance and fluorescence quantum efficiency, and achieves high efficiency and long ser...
|
|
WO/2023/286817A1 |
The present invention provides: a material which enables a photoelectric conversion element for image pickup to have higher sensitivity and higher resolution; and a photoelectric conversion element which uses this material. A material fo...
|
|
WO/2023/287783A1 |
The present disclosure relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods comprising a compound of any one of Formulas (I), (II), (III), and (IV) as further described...
|
|
WO/2023/287252A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2023/284807A1 |
A compound containing a tetrahydronaphthyridone or tetrahydropyridopyrimidinone skeleton as shown in formula (I), and a preparation method therefor; as verified through experiments, the compound containing a tetrahydronaphthyridone or te...
|
|
WO/2023/285787A1 |
A process for preparing a compound of formula I, or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula I.
|
|
WO/2023/287255A1 |
The present invention relates to: a compound represented by chemical formula 1; and an organic light-emitting device comprising a first electrode, a second electrode, and one or more organic layers provided between the first electrode an...
|
|
WO/2023/288264A1 |
One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to trea...
|
|
WO/2023/284022A1 |
Provided are a phenanthroimidazole derivative, and a preparation method therefor and an application thereof. The phenanthroimidazole derivative has a structural formula as shown in formula (I), R being an electron donor group, wherein by...
|
|
WO/2023/285788A1 |
A process for preparing a compound of formula (I), or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula (I).
|
|
WO/2023/283256A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/280283A1 |
The present invention relates to a compound used as an SHP2 inhibitor and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula I', wherein the definitions of each group and each s...
|
|
WO/2023/281521A1 |
SILVER ANTIMICROBIALS Disclosed is a method (100) for synthesizing an antimicrobial base. The method (100) comprises treating a Silver salt in a reaction mixture. The method (100) further comprises adding one or more reactants to the rea...
|
|
WO/2023/282676A1 |
The present specification relates to a compound and an organic light-emitting element comprising same.
|
|
WO/2023/282702A1 |
Provided are an inhibitor of SHP2, a pharmaceutical composition for preventing or treating diseases related to SHP2 comprising same, a method for treating and preventing diseases using same, and a use thereof. According to the present in...
|
|
WO/2023/282236A1 |
This rare earth complex is represented by a general formula (1). (In the formula, HC is a quinolinonato ligand and cumalinato ligand; L1 is a nitrogen-containing ligand, etc.; L2 is water, etc.; XL is a halide ion, etc.; M3+ is a trivale...
|
|
WO/2023/283080A1 |
The present disclosure relates to solid state forms of Telatinib and Telatinib mesylate, processes for their preparation, and pharmaceutical compositions thereof (I).
|
|
WO/2023/283269A1 |
Disclosed herein is a specific crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-
6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide (ABT-101) free base, the pharmaceutical composition and capsule c...
|
|
WO/2023/280309A1 |
The present disclosure relates to salt types of a tricyclic tetrahydro isoquinoline derivative. Specifically, the present disclosure relates to different salt types of a compound as represented by formula (I) and a preparation method the...
|
|
WO/2023/280290A1 |
The present invention relates to a class of pyrrole sulfonyl derivatives, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug. Specifically, the present invention ...
|
|
WO/2023/280317A1 |
Provided are a benzylamino tricyclic compound and the use thereof, which in particular relate to a compound as represented by formula (Ⅹ), and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/273384A1 |
Provided in the present disclosure are a thermally activated delayed fluorescent material, an organic light-emitting device and a display apparatus. The energy level difference between a singlet energy level and a triplet energy level of...
|
|
WO/2023/276918A1 |
A compound represented by the following general formula is an excellent electronic barrier material. X represents a donor group; R1 to R6 represent substituents; and n1 to n6 represent integers greater than or equal to 0 and less than or...
|
|
WO/2023/277656A1 |
The present invention relates to a novel benzopyran derivative useful for preparing a drug for treating cancer, and more specifically, to a novel benzopyran derivative which is a micromolecule having a macrophage inhibitory effect and is...
|
|
WO/2023/279105A1 |
Provided herein are azetidine pyrimidine compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or with therapeutic agents. The compounds provided ...
|
|
WO/2023/277313A1 |
The present invention relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2023/277289A1 |
The present application provides: a heterocyclic compound; and an organic light-emitting device which comprises an organic layer containing the heterocyclic compound.
|
|
WO/2023/278729A1 |
The present application provides radioisotope-containing compounds that are, e.g., mGluR2 modulators. Methods of imaging brain of a patient, as well as methods of diagnosing and monitoring treatment of psychiatric or neurological disorde...
|
|
WO/2023/277446A1 |
The present specification relates to a heterocyclic compound, an organic light-emitting device comprising same, and a composition for an organic layer.
|
|
WO/2023/279041A1 |
Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.
|
|
WO/2023/277645A1 |
The invention relates to an organic molecule for the application in optoelectronic devices. According to the invention, the organic molecule has - a first chemical moiety comprising of a structure of formula I: Formula I and - one or two...
|
|
WO/2022/267945A1 |
The present invention belongs to the field of medicine and relates to a method for preparing pranoprofen. The present invention further relates to a composition containing pranoprofen and an impurity, a quality control method, and an int...
|
|
WO/2022/272154A2 |
Disclosed herein are pharmaceutical compositions comprising biosynthetic allosteric mTOR inhibitors that can have improved pharmacology and reduced toxicity. Also disclosed herein are methods of treating a condition or disease by adminis...
|
|
WO/2022/270592A1 |
This compound represented by a general formula is useful as an electron barrier material. R1 through R5 are a deuterium atom, a substituent other than a cyano group; n1, n3, n5 are 0-4; n2 is 0-3; n4 is 0-2; X is O or S; and Ar is a mono...
|
